Alfred Belen, MD
Psychiatry · Lewiston, NYNPI 1386776847
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 423 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$1K
- Otsuka America Pharmaceutical, Inc.$919
- AbbVie$879
- Takeda Pharmaceuticals U.S.A., Inc.$727
- Teva Pharmaceuticals USA, Inc.$628
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$621
- plus $3K from 24 others
Across 105 payments — averaging $1408.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$148K
What the payments were for
- Food & beverage$7,45096%
- Education$3154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 87 | $1,435 |
| Otsuka America Pharmaceutical, Inc. | 55 | $919 |
| AbbVie(2 entities) | 54 | $879 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $727 |
| Teva Pharmaceuticals USA, Inc. | 29 | $628 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $621 |
| Neurocrine Biosciences, Inc. | 20 | $532 |
| Lundbeck LLC | 18 | $370 |
| Axsome Therapeutics, Inc. | 13 | $268 |
| Johnson & Johnson | 22 | $216 |
| Idorsia Pharmaceuticals US Inc | 10 | $177 |
| Alkermes, Inc. | 5 | $116 |
| Livanova USA, Inc. | 4 | $115 |
| Sage Therapeutics, LLC | 1 | $111 |
| AstraZeneca | 6 | $100 |
| Neos Therapeutics, LP | 2 | $85 |
| Vifor Pharma, Inc. | 3 | $66 |
| Biogen | 3 | $54 |
| Amgen | 3 | $47 |
| Neuronetics, Inc. | 2 | $44 |
| Merck | 3 | $42 |
| Bausch Health US, LLC | 2 | $42 |
| Ironshore Pharmaceuticals Inc. | 2 | $38 |
| Sunovion Pharmaceuticals Inc. | 1 | $34 |
| Medtronic | 1 | $24 |
| OWP Pharmaceuticals, Inc. | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $12 |
| GE HealthCare | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,765 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 40 | $61,781 |
| RexultiBrexpiprazole | 36 | $51,500 |
| AuvelityDextromethorphan Hbr/Bupropion | 49 | $40,979 |
| TrintellixVortioxetine Hydrobromide | 68 | $36,001 |
| CaplytaLumateperone Tosylate | 21 | $33,640 |
| NuvigilArmodafinil | 13 | $25,147 |
| FanaptIloperidone | 11 | $22,032 |
| BelsomraSuvorexant | 14 | $6,041 |
| Duloxetine Hcl | 172 | $4,248 |
| Lamotrigine | 352 | $3,899 |
| Quetiapine Fumarate | 153 | $2,988 |
| Varenicline Tartrate | 13 | $2,751 |
| Aripiprazole | 87 | $2,687 |
| Clomipramine Hcl | 11 | $2,648 |
| Bupropion XlBupropion Hcl | 115 | $2,341 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $879 | $61,78140 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $919 | $51,50036 claims |
| Axsome Therapeutics, Inc.Auvelity | $268 | $40,97949 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $727 | $36,00168 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $621 | $33,64021 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,435 | $22,03211 claims |
| MerckBelsomra | $42 | $6,04114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Lewiston
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.